Cabaletta Bio | LinkedIn (original) (raw)
``
Biotechnology Research
Philadelphia, Pennsylvania 12,868 followers
Engineered T cell therapies designed for the treatment of patients with autoimmune diseases
About us
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Philadelphia, Pennsylvania
Type
Public Company
Founded
2017
Specialties
cell therapy, biotech, immunology, autoimmune, and rheumatology
Locations
Employees at Cabaletta Bio
Updates
- Today, Cabaletta Bio outlined our strategic priorities and anticipated key milestones for 2025. We announced plans to meet with the FDA to align on registrational trial designs in 1H25 based on the emerging clinical profile of rese-cel (resecabtagene autoleucel, formerly CABA-201) and increased pace of enrollment with 44 active clinical trial sites across the RESET program. Read the press release here: https://lnkd.in/eR8CzchE #CART #celltherapy #reset #autoimmune
- This morning, Cabaletta Bio announced positive clinical data on CABA-201 demonstrating the potential to achieve compelling clinical responses with all patients discontinuing all immunosuppressants in the first 8 patients dosed across the ongoing Phase 1/2 RESET-Myositis™, RESET-SLE™ and RESET-SSc™ clinical trials. Read our press release on the News & Media section of our website and join our live investor conference call and webcast today at 8:00a.m. EDT here: https://lnkd.in/eS5EF2gs #celltherapy #myositis #SLE #SSc #reset #autoimmune
- Join us for an interactive Innovation Theater at ACR Convergence 2024 on Monday, November 18th at 10:30a ET, featuring David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for systemic lupus erythematosus in the US in over 60 years, and Iain McInnes, Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow and a member of our Scientific Advisory Board. We will be discussing emerging clinical & translational data in the field of CAR T cell therapy and an update of the RESET clinical trial program. We look forward to seeing you there! #reset #ACR24 #CART #celltherapy #autoimmune
- Today, Cabaletta Bio reported 16 patients enrolled with 10 patients dosed across the RESET™ clinical development program as of November 12. There are 40 U.S. clinical sites actively enrolling patients across 5 RESET clinical trials. We are looking forward to presenting clinical data in lupus, myositis, and systemic sclerosis in oral and poster presentations this weekend at ACR Convergence 2024. We also announced that we have expanded clinical development into Europe with EMA CTA authorization for CABA-201 received in lupus and expanded our leadership team with the hires of Gerwin Winter and Nicolette Sherman. Read our Q3 2024 earnings press release here: https://lnkd.in/evmi4RSu #CART #celltherapy #reset #autoimmune
-
12,868 followers
2mo Edited
Cabaletta Bio is looking forward to the American College of Rheumatology Convergence 2024 Conference this month in Washington D.C. Join us for an interactive Innovation Theater on Monday, November 18th at 10:30a ET, featuring David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for SLE in the US in over 60 years, and Iain McInnes, Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow and a member of our Scientific Advisory Board. We will be discussing emerging clinical & translational data in the field of CAR T cell therapy and an update of the RESET clinical trial program. Look forward to seeing you there! #reset #ACR24 #CART #celltherapy #autoimmune
Join now to see what you are missing
Similar pages
- Kyverna Therapeutics Biotechnology Research Emeryville, California
- Carisma Therapeutics Biotechnology Research Philadelphia, Pennsylvania
- Verismo Therapeutics Biotechnology Research Philadelphia, Pennsylvania
- Century Therapeutics, Inc Biotechnology Philadelphia, Pennsylvania
- Spark Therapeutics, Inc. Biotechnology Research Philadelphia, PA
- Adaptimmune Biotechnology Research Abingdon, Oxfordshire
- Allogene Therapeutics Biotechnology South San Francisco, California
- Passage Bio Biotechnology Research Philadelphia, Pennsylvania
- Sonoma Biotherapeutics Biotechnology Research South San Francisco, California
- Interius BioTherapeutics Biotechnology Research Philadelphia, Pennsylvania